DARTBAC will, from a material perspective, develop new antimicrobial technologies that are not based on antibiotics to target infection prevention and eradication on implant surfaces, in hard tissues and in soft tissues. In this way, we are unique yet synergistic with most other initiatives that focus on an antibiotics approach. 
Collectively, we are bringing the entire knowledge-chain regarding development of new material
technologies to combat AMR.


DARTBAC will develop a new workflow based on AOPs of predictive in vitro and in vivo models to test safety and efficacy of newly developed antimicrobial technology in order to shorten the time to market. DARTBAC will enhance the therapeutic efficacy of current antibiotics by combination therapy and we will develop and validate these technologies so that they can be brought to the market within the project timeframe.
Finally, we will maintain awareness of the emerging AMR problem in the Netherlands by informing the general public and HealthCare Practitioners (HCPs). This increased AMR awareness by HCPs, the general public, and healthcare policy makers can speed up acceptance and market introduction of these technologies both nationally and internationally. Moreover, such acceptance will ensure that insurance providers and advisory bodies adopt and reimburse new treatment approaches quicker, thereby accelerating clinical implementation.


A successful DARTBAC project with the combination of these goals and objectives can prevent a rise in infection percentage due to AMR, minimize the effect of AMR in the Netherlands, and work towards a Dutch society that is less dependent on antibiotic therapy for infection, prevention, and treatment.

DARTBAC is an interdisciplinary, 23 partner consortium consisting of 
(a) academic partners with expertise on infection, materials, imaging, in vitro models and social sciences; 
(b) technical university partners with expertise on material science, imaging, and in vitro and in vivo test models; 
(c) university medical centres with expertise on infection, microbiology, in vitro and in vivo models, imaging, animal models, material technology, and clinical studies; 
(d) small and large medical device companies and start-up companies with antimicrobial technologies; (e) scientific societies and knowledge institute of medical specialists with direct access to our target audience and patient groups for communication and dissemination; 
(f) the Dutch National Institute for Public Health and the Environment (RIVM) with expertise on materials science and Adverse Outcome Pathways (AOPs); and 
(g) an international knowledge platform on AMR with expertise on AMR communication. 

DARTBAC will

From a material perspective, develop new antimicrobial technologies that are not based on antibiotics to target infection prevention and eradication on implant surfaces, in hard tissues, and in soft tissues.
Assess safety and efficacy of these newly developed antimicrobial technologies.
Enhance the therapeutic efficacy of current antibiotics by combination therapy.
Develop a new workflow based on AOPs (adverse outcome pathways) of predictive in vitro and in vivo models to test safety and efficacy of newly developed antimicrobial technology in order to shorten the time to market.
Maintain awareness of the emerging AMR problem in the Netherlands by informing the general public and HCPs.

4 pillars

1. AMR awareness general public and health care professionals
2. AB therapy optimalisation with combination therapy
3. New technology development, safety & efficacy assessment; validation for soft tissue, hard tissue and implant surfaces
4. Development standardized models to bring future technology faster toward clinical implementation

Knowledge gaps

Plan of action

5 Research lines / demonstrators

Research line 1
Awarenes
WP-2, 9
Research line 2
Microbiology
WP-3,4,5,6,7,8
Research line 3
Imaging
WP-3,4,5,6,7,8
Research line 4
Technology development
WP-3,4,5,6,7,8
Research line 5
Model development
WP-2, 3,4, 8
The DARTBAC project will prepare the Netherlands for the time when antibiotics are much less effective in the prevention and eradication of infection due to AntiMicrobial Resistance (AMR)
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram